Galena Biopharma (GALE) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS
Galena Biopharma (NASDAQ: GALE) released its earnings data on Tuesday. The company reported ($0.53) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.62) by $0.09.
A number of research firms have also recently commented on GALE. Analysts at Zacks reiterated an “outperform” rating on shares of Galena Biopharma in a research note to investors on Friday, February 8th. They now have a $4.00 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Galena Biopharma in a research note to investors on Monday, December 31st. They set an “overweight” rating and a $2.50 price target on the stock.
Galena Biopharma (GALE) traded up 5.42% on Tuesday, hitting $2.14. Galena Biopharma (GALE) has a 52-week low of $1.04 and a 52-week high of $3.54. The stock’s 50-day moving average is currently $1.85. The company’s market cap is $144.7 million.
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using RNAi-targeted and immunotherapy technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.